Unitas Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 6.00 M
as on 16-06-2024
- Paid Up Capital ₹ 5.21 M
as on 16-06-2024
- Company Age 30 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.13 Cr
as on 16-06-2024
- Satisfied Charges ₹ 1.00 M
as on 16-06-2024
- Revenue -3.00%
(FY 2023)
- Profit 180.07%
(FY 2023)
- Ebitda -23.76%
(FY 2023)
- Net Worth 126.54%
(FY 2023)
- Total Assets 1.95%
(FY 2023)
About Unitas Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.00 M and a paid-up capital of Rs 5.21 M.
The company currently has active open charges totaling ₹5.13 Cr. The company has closed loans amounting to ₹1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Akhilesh Nagar and Neelam Nijhawan serve as directors at the Company.
- CIN/LLPIN
U74899DL1994PTC057671
- Company No.
057671
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Mar 1994
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
New Delhi, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Unitas Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Akhilesh Nagar  | Director | 02-Mar-1994 | Current |
| Neelam Nijhawan | Director | 14-Jan-2001 | Current |
Financial Performance of Unitas Pharmaceuticals.
Unitas Pharmaceuticals Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 3% decrease. The company also saw a substantial improvement in profitability, with a 180.07% increase in profit. The company's net worth Soared by an impressive increase of 126.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Unitas Pharmaceuticals?
In 2023, Unitas Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 24 May 2023 | ₹2.43 M | Open |
Others Creation Date: 30 Jul 2013 | ₹2.74 Cr | Open |
State Bank Of India Creation Date: 02 Apr 2003 | ₹2.15 Cr | Open |
How Many Employees Work at Unitas Pharmaceuticals?
Unlock and access historical data on people associated with Unitas Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Unitas Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Unitas Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
